Why drugmakers are telling Donald Trump to cool his heels
Nine pharmaceutical giants pledge to uphold scientific and ethical standards rather than rush a coronavirus vaccine
THE WORLD’S 7.5bn people want a vaccine for covid-19 as soon as possible. One person needs it by November 3rd. As President Donald Trump limps towards election day, he wants to report real medical progress against the disease. Earlier this year it seemed possible that one or two pharmaceutical firms might be able to obtain some sort of limited approval by the time Americans cast their ballots. That may still be possible. It is certainly desirable, given the pandemic’s toll on lives and livelihoods. But on September 8th, in an unprecedented move, nine global drugmakers, including AstraZeneca, GSK, Pfizer and Sanofi, announced a pledge to uphold scientific and ethical standards in the search for a coronavirus vaccine.
This article appeared in the Business section of the print edition under the headline “Strong medicine”
Business September 12th 2020
- Can Reed Hastings preserve Netflix’s culture of innovation as it grows?
- Why drugmakers are telling Donald Trump to cool his heels
- Who will win the brewing battle between Japan and America?
- Nongfu Spring is a hit with tipplers and investors alike
- How America’s war on Huawei may boost Chinese technology
- Management lessons from Honeywell’s former CEO
- How Hermès got away from LVMH—and thrived
From the September 12th 2020 edition
Discover stories from this section and more in the list of contents
Explore the editionDiscover more
Could seaweed replace plastic packaging?
Companies are experimenting with new ways to reduce plastic waste
Has Sequoia Capital outgrown its business model?
Venture capital’s hardiest perennial gets back to its roots
On stupid rules and quick wins
Why every boss can benefit from asking employees what most infuriates them
TikTok wants Western consumers to shop like the Chinese
It still has some convincing to do
Will the trouble ever end for Volkswagen and its rivals?
From strikes to Trump tariffs, calamities abound
After Northvolt’s failure, who will make Europe’s EV batteries?
The continent looks ever more reliant on Asian producers